The adjunctive effect of nebulized furosemide in COPD exacerbation: A randomized controlled clinical trial

Respiratory Care

Volumn 58, Issue 11, 2013, Pages 1873-1877

  Motahar Vahedi, Hojat Sheikh ^a   Mahshidfar, Babak ^b   Rabiee, Helaleh ^c   Saadat, Soheil ^c   Shokoohi, Hamid ^d   Chardoli, Mojtaba ^e   Rahimi Movaghar, Vafa ^c,f  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Arterial blood gas; Bronchodilation; COPD; Dyspnea; Nebulized furosemide

Indexed keywords

FUROSEMIDE; PLACEBO;

AGED; ARTERIAL GAS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NEBULIZATION; PH MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ARTERIAL BLOOD GAS; BRONCHODILATION; COPD; DYSPNEA; NEBULIZED FUROSEMIDE;

ADMINISTRATION, INHALATION; AGED; BLOOD PRESSURE; BRONCHOCONSTRICTION; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; FUROSEMIDE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84886256808     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02160     Document Type: Article

References (26)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532-555.
2. Fromer L, Cooper CB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract 2008;62(8):1219-1236.
3. Ora J, Jensen D, O'Donnell DE. Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. Curr Opin Pulm Med 2010;16(2):144-149.
4. Seamark DA, Seamark CJ, Halpin DM. Palliative care in chronic obstructive pulmonary disease: a review for clinicians. J R Soc Med 2007;100(5):225-233.
5. Horton R, Rocker G. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. Curr Opin Support Palliat Care 2010;4(2):56-62.
6. Undem BJ, Kollarik M. The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2(4):355-360; discussion 371-352.
7. Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1(3):289-304.
8. Nishino T. Dyspnoea: underlying mechanisms and treatment. Br J Anaesth 2011;106(4):463-474.
9. Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care 2007;52(7):900-910.
10. Sudo T, Hayashi F, Nishino T. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am J Respir Crit Care Med 2000;162(3 Pt 1):971-975.
11. Moosavi SH, Binks AP, Lansing RW, Topulos GP, Banzett RB, Schwartzstein RM. Effect of inhaled furosemide on air hunger induced in healthy humans. Respir Physiol Neurobiol 2007;156(1):1-8.
12. Nishino T, Ide T, Sudo T, Sato J. Inhaled furosemide greatly alleviates the sensation of experimentally induced dyspnea. Am J Respir Crit Care Med 2000;161(6):1963-1967.
13. Rodriguez Vazquez JC, Pino Alfonso PP, Gassiot Nuno C, Paez Prats I, Fernandez Manzano E. Assessment of the bronchodilator effect of inhaled furosemide compared to salbutamol in asthmatic patients. J Investig Allergol Clin Immunol 1998;8(2):115-118.
14. Shimoyama N, Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002;23(1):73-76.
15. Kohara H, Ueoka H, Aoe K, Maeda T, Takeyama H, Saito R, et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003;26(4):962-967.
16. Ong KC, Kor AC, Chong WF, Earnest A, Wang YT. Effects of inhaled furosemide on exertional dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169(9):1028-1033.
17. Jensen D, Amjadi K, Harris-McAllister V, Webb KA, O'Donnell DE. Mechanisms of dyspnoea relief and improved exercise endurance after furosemide inhalation in COPD. Thorax 2008;63(7):606-613.
18. Currow DC, Ward AM, Abernethy AP. Advances in the pharmacological management of breathlessness. Curr Opin Support Palliat Care 2009;3(2):103-106.
19. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(5 Pt 2):S77-121.
20. Niewoehner DE, Collins D, Erbland ML. Relation of FEV1 to clinical outcomes during exacerbation of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000;161(4 Pt 1):1201-1205.
21. Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. Am J Respir Crit Care Med 1999;160(3):1028-1030.
22. Whale CI, Sovani MP, Mortimer K, Oborne J, Cooper S, Harrison TW, et al. Effects of rac-albuterol on arterial blood gases in patients with stable hypercapnic chronic obstructive pulmonary disease. Br J Clin Pharmacol 2006;62(2):153-157.
23. Ando F, Ruggeri P, Girbino G, Cazzola M. Tiotropium and salmeterol/ fluticasone combination do not cause oxygen desaturation in COPD. Respir Med 2008;102(6):815-818.
24. Stephenson A, Seitz D, Bell CM, Gruneir A, Gershon AS, Austin PC, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011;171(10):914-920.
25. Brijker F, Heijdra YF, van den Elshout FJ, Folgering HT. Discontinuation of furosemide decreases PaCO2 in patients with COPD. Chest 2002;121(2):377-382.
26. Minowa Y, Ide T, Nishino T. Effects of inhaled furosemide on CO2 ventilatory responsiveness in humans. Pulm Pharmacol Ther 2002;15(4):363-368.